ECTRIMS 2016: Alemtuzumab Benefits Continue Six Years Post-Treatment
Executive Summary
The continuing benefits of Sanofi’s multiple sclerosis therapy Lemtrada six years after two short courses bolster the case for its use early in the course of the disease.
You may also be interested in...
Lemtrada 'Behaves Like Chemotherapy For MS' Suggests 5-Year Efficacy Data
Around two thirds of patients on Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) need no additional treatment up to four years after the two courses of infusion that make up its standard treatment schedule, according to Genzyme's Mike Panzara, therapeutic area head of MS, neurology and ophthalmology.
Genzyme Nabs Elusive Lemtrada Approval, But As Third-Line MS Therapy
FDA says therapy for relapsing multiple sclerosis should be reserved for patients who fail two or more other MS treatments; REMS includes four-year follow up.
Genzyme gears up for Lemtrada EU launch amid stiff MS competition
The European Commission has approved Genzyme's MS drug Lemtrada (alemtuzumab), making the EU the first launch market for the product, but it will face tough competition from MS drugs already on the market, particularly Biogen Idec's Tysabri (natalizumab).